Search clinical trials for: Desvenlafaxine succinate

Total 426 results

Seoul National University Hospital
Pfizer; Seoul National University Bundang Hospital; Korea Cancer Center Hospital

Terminated

Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

Breast Neoplasms | Hot Flashes

Korea, Republic of
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Pfizer

Completed

Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Major Depressive Disorder

Canada, United States, Colombia, Croatia, Estonia, Finland, Poland, France, Slovakia, Chile, Latvia, Lithuania, Romania, South Africa
Wyeth is now a wholly owned subsidiary of Pfizer
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Pfizer

Completed

Study Comparing Discontinuation Symptoms Of DVS SR In Subjects With Major Depressive Disorder (MDD)

Major Depressive Disorder
University of Ottawa

Unknown

Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers (DVS)

Healthy

Canada
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Tolerability and Pharmacokinetics of Desvenlafaxine Succinate SR in Healthy Chinese Male and Females

Healthy
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Chile, Mexico
Pfizer

Terminated

Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients

Vasomotor Symptoms | Major Depressive Disorder

Philippines
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women

Vasomotor Symptoms
Pfizer

Completed

Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women

Vasomotor Symptoms

Canada, United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of the Safety and Efficacy of Desvenlafaxine Succinate for Vasomotor Symptoms in Postmenopausal Women

Menopause | Vasomotor System

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Peri- And Postmenopausal Women With Major Depressive Disorder (DVS 3364)

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Depressive Disorder, Major
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating the Long-Term Safety of Desvenlafaxine Succinate Sustained-Release (DVS SR) in Subjects With Pain Associated With Diabetic Peripheral Neuropathy

Diabetic Neuropathy, Painful
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR) In The Treatment Of Child and Adolescent Outpatients With Major Depressive Disorder

Depressive Disorder, Major Depressive Disorder

United States
Pfizer

Completed

Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)

Major Depressive Disorder

Japan
Pfizer

Completed

Phase 1 Study To Test the Bioequivalence Between Two 25 mg Tablets vs. One 50 mg Tablet Under Fast/Fed Condition and Evaluate Food Effect of Desvenlafaxine Succinate Sustained Release (DVS SR)

Depression - Major Depressive Disorder

Belgium
Pfizer

Completed

The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms

Vasomotor Symptoms

Canada, United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Child And Adolescent Outpatients With Major Depressive Disorder

Depression | Major Depressive Disorder

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Major Depressive Disorder

United States, Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

Depressive Disorder, Major

Finland, France, South Africa, Estonia, Croatia, Lithuania, Latvia, Slovakia, Poland, Romania
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

United States
Jiangsu Province Nanjing Brain Hospital

Recruiting

Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustained-release Tablets Targeting Anhedonia in Patients With Major Depression Disorder

Anhedonia

China
Mochida Pharmaceutical Company, Ltd.
Pfizer

Completed

A Study of MD-120 in Patients With Depression

Major Depressive Disorder

Japan
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Desvenlafaxine in Treating Major Depressive Disorder.

Major Depressive Disorder

China
Corporacion Parc Tauli
Pfizer

Unknown

Switching From SSRI to Desvenlafaxine on Cognitive Functioning

Major Depressive Disorder

Spain
Assistance Publique - Hôpitaux de Paris
Groupe Hospitalier Paris Saint Joseph; French National Network of Clinical...

Completed

Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections (TEMO-CARB)

Urinary Tract Infections

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

Depressive Disorder | Depression | Depressive Disorder, Major

Colombia, Mexico, United States, Peru, Chile, Argentina
BC Women's Hospital & Health Centre

Completed

Functional Outcome in Postpartum Depression in Women Treated With Desvenlafaxine

Depression

Canada
University of British Columbia
Pfizer

Completed

Neurocognition and Work Productivity in Major Depressive Disorder (MDD)

Major Depressive Disorder

Canada
Pfizer

Completed

Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet

Major Depressive Disorder

Korea, Republic of
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

Healthy

United States
Luye Pharma Group Ltd.

Completed

Pilot BA Study of New LY03005 vs Pristiq

Major Depression

United States
Luye Pharma Group Ltd.

Completed

A Relative Bioavailability Food Effect Study of LY03005

Major Depressive Disorder

United States
Centre de Recherche de l'Institut Universitaire...
Pfizer

Unknown

Effect of Antidepressants on White Matter Structure

Major Depression

Canada
START Clinic for Mood and Anxiety Disorders

Completed

Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities

Generalized Anxiety Disorder

Canada
Luye Pharma Group Ltd.

Completed

A Study of LY03005 vs Pristiq

Major Depressive Disorder

United States
Centre for Addiction and Mental Health

Completed

Desvenlafaxine Monotherapy in Dysthymia

Dysthymic Disorder

Canada
Unity Health Toronto

Completed

Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment

Depression | Anhedonia

Canada
The Medical Research Network
Pfizer

Completed

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

Social Anxiety Disorder

United States
University of Calgary
University of Alberta

Unknown

Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis

Major Depressive Disorder

Canada
New York State Psychiatric Institute
Pfizer

Completed

Desvenlafaxine vs. Placebo Treatment of Chronic Depression

Dysthymia | Dysthymic Disorder | Chronic Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS SR in Patients With Fibromyalgia Syndrome

Fibromyalgia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating DVS-233 for Treatment of Outpatients With Major Depressive Disorder

Major Depressive Disorder
Luye Pharma Group Ltd.

Completed

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Major Depressive Disorder

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evalutating the Pharmacokinetics (PK) and Safety of a Single Dose of Desvenlafaxine Sustained Release (DVS SR)

Depressive Disorder, Major

United States
Luye Pharma Group Ltd.

Completed

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

Major Depressive Disorder, Recurrent, Unspecified

United States
Pfizer

Completed

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder

Depressive Disorder, Major

United States
Pfizer

Completed

A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD

Major Depressive Disorder

United States, Mexico

3

Subscribe